RxDoctor Payments Data

Casey Godshall, MD

Infectious Disease · Farmington, CTNPI 1588958227

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Gilead at 44.8% of the total. Reporting peaked in 2019 at $571 and has fallen 95.6% since, to $25 in 2023.

$1,084in general payments, 2019–2025

Across 64 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$486
  • Johnson & Johnson$285
  • Viiv Healthcare Company$176
  • AbbVie$49
  • Novo Nordisk$48
  • Merck$39

What the payments were for

  • Food & beverage$1,084100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead31$486
Johnson & Johnson18$285
Viiv Healthcare Company8$176
AbbVie3$49
Novo Nordisk2$48
Merck2$39

How this compares

$1,084 in reported general payments places this provider in the 70th percentile of 159 infectious disease providers in Connecticut.

See all infectious disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$15,365
Medicare patients
70
Services billed
127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala115$482,093
TivicayDolutegravir Sodium56$126,586
PrezcobixDarunavir/Cobicistat35$99,302
DovatoDolutegravir Sodium/Lamivudine31$92,105
TriumeqAbacavir/Dolutegravir/Lamivudi20$91,312
JulucaDolutegravir/Rilpivirine19$72,284
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf13$70,692
DescovyEmtricitabine/Tenofov Alafenam18$37,569
Cefadroxil17$898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$486$519,662133 claims
Viiv Healthcare CompanyTivicay, Dovato, Triumeq, Juluca$176$382,287126 claims
Johnson & JohnsonPrezcobix$285$99,30235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 159 infectious disease providers in Connecticut.

Other infectious disease in Farmington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →